On February 4, 2021, the U.S. antitrust agencies announced that they are temporarily suspending the discretionary practice of granting early termination of the waiting period to filings made under the Hart-Scott-Rodino ("HSR") Act. Since January 16, the agencies granted ET in just one transaction, which involved diagnostic tests for COVID-19. The current pause, as articulated, does not include any exceptions, for example, for deals involving pandemic-related products. The HSR Act requires parties
The US FTC and the US DoJ announce the suspension of the discretionary practice of granting early termination of the waiting period to filings made under the Hart-Scott-Rodino Act
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.